Soonchunhyang University Cheonan Hospital Begins Development of New Drug for Ovarian Cancer

Selected for the Ministry of Trade, Industry and Energy Supported 'Multi-omics Based Customized Diagnosis and Treatment Commercialization Technology Development Project for Intractable Cancer'

Chunan Hospital, affiliated with Soonchunhyang University, has been selected for the "Multi-omics Based Commercialization Technology Development Project for Personalized Diagnosis and Treatment of Refractory Cancer," supported by the Ministry of Trade, Industry and Energy, and has embarked on discovering new therapeutic targets and developing new drugs for ovarian cancer.

The research team is led by Professor Jeon Seop from the Department of Obstetrics and Gynecology at Soonchunhyang University Cheonan Hospital, with participation from Professor Kang Donghyun of the Department of Colorectal Surgery, Professor Yang Eunjeong of Obstetrics and Gynecology, Professor Ryu Seongho from the Soonchunhyang Institute of Medical Science (SIMS), Professor Lim Jeonggyun from the Department of Nano Chemical Engineering at Soonchunhyang University, and CEO Bang Jeonggyu of Dandicure Co., Ltd. A total of 3.8 billion KRW will be invested until December 2028.

Ovarian cancer, considered one of the refractory cancer types, is mostly diagnosed at advanced stages of stage 3 or higher, resulting in very poor prognosis. In particular, recurrent cancers that show resistance to chemotherapy, targeted therapy, and immunotherapy lack effective treatments, making new drug development urgent.

The research team plans to identify therapeutic targets (POI, Protein of Interest) through multi-omics analysis using exosomes and tissues from ovarian cancer patients’ blood, develop PROTAC (Proteolysis Targeting Chimera) technology for degrading ovarian cancer-inducing target proteins, and create effective drug delivery systems to develop optimized new drugs for ovarian cancer treatment.

Professor Jeon Seop, the principal investigator, stated, “We will do our best to increase the survival rate and improve the quality of life for ovarian cancer patients through effective new drug development, bringing hope to those suffering from ovarian cancer.”

This content was produced with the assistance of AI translation services.